Novel agents or imatinib for CML in the frontline setting?

Novel agents or imatinib for CML in the frontline setting?

VJHemOnc

1 year
74 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
With the many new second generation therapies for chronic myeloid leukemia (CML), there is some debate as to which therapy should be used in the first-line setting, and indeed whether the existing standard of care, imatinib, is adequate. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Richard Clark, MA, MD, MRCP, FRCPath, of the Royal Liverpool University Hospital, Liverpool, UK, gives his opinion on this contentious topic. He says that while response is greater with novel therapies, toxicity is also increased relative to imatinib. He suggests that new prognostic markers should be developed to accurately determine which patients will respond sufficiently to imatinib, and which patients require more aggressive frontline treatment.
Up Next Autoplay
Treating CML & Myelofibrosis Patients
Treating CML & Myelofibrosis Patients
Category: Chronic Myelogenous Leukemia
317 Views
imedex 10 months
Resistance/intolerance to second generation TKIs in CML: what to do next?
Resistance/intolerance to second generation TKIs in CML: what to do next?
Category: Chronic Myelogenous Leukemia
153 Views
VJHemOnc 1 year
Update on ENESTop: TFR in CML after discontinuing nilotinib
Update on ENESTop: TFR in CML after discontinuing nilotinib
Category: Chronic Myelogenous Leukemia
126 Views
VJHemOnc 1 year
Benefits of second generation TKIs for CML in the frontline
Benefits of second generation TKIs for CML in the frontline
Category: Chronic Myelogenous Leukemia
92 Views
VJHemOnc 1 year
Personalized therapy in leukemia: a case study
Personalized therapy in leukemia: a case study
Category: Chronic Myelogenous Leukemia
236 Views
VJHemOnc 1 year
New drugs for CML: are more to come?
New drugs for CML: are more to come?
Category: Chronic Myelogenous Leukemia
63 Views
VJHemOnc 1 year
Bosutinib: a new, safer TKI for frontline CML
Bosutinib: a new, safer TKI for frontline CML
Category: Chronic Myelogenous Leukemia
92 Views
VJHemOnc 1 year
Asciminib has the potential to succeed where other TKIs have failed in CML
Asciminib has the potential to succeed where other TKIs have failed in CML
Category: Chronic Myelogenous Leukemia
209 Views
VJHemOnc 1 year
DESTINY: achieving TFR by de-escalating therapy in CML
DESTINY: achieving TFR by de-escalating therapy in CML
Category: Chronic Myelogenous Leukemia
97 Views
VJHemOnc 1 year